Where Will Bristol Myers Squibb Be in 5 Years?

The drugmaker will go through key changes by the end of the decade.Bristol Myers Squibb (BMY 0.51%) has had a rough past five years. Its shares are barely in the green, its financial results have been unimpressive, and it has faced important patent cliffs. Most notably, its cancer drug Revlimid, its top-selling product at one point, is now out of patent exclusivity.Despite that poor showing in recent years, things might be very different for BMS in the next half-decade, but only if it can better handle the ...